Table 3.
The Means of the Similarity (C) for the Intra-healthy Treatment, Intra-diseased Treatment, as well as Wilcoxon Tests for Detecting the AKP Effects: C(H)>C(D) Indicating AKP Effects, C(H)<C(D) Indicating Anti-AKP Effects, C(H) = C(D) Indicating Non-AKP Effects
| Site | Disease Case Study | Index | Treatments |
Similarity (C) |
p Value of Wilcoxon Test |
||||
|---|---|---|---|---|---|---|---|---|---|
| Healthy (H) | Diseased (D) | Healthy (H) | Diseased (D) | ≠ | > | < | |||
| Gut | IBD (Inflammatory Bowel Disease) | 1 | Healthy | CD | 0.124 | 0.128 | 0.776 | 0.612 | 0.388 |
| Healthy | UC | 0.124 | 0.060 | 0.000 | 0.000 | 1.000 | |||
| 2 | Healthy | CD | 0.108 | 0.065 | 0.000 | 0.000 | 1.000 | ||
| Healthy | UC | 0.108 | 0.110 | 0.001 | 1.000 | 0.000 | |||
| Obesity | 3 | Lean | Overweight | 0.121 | 0.125 | 0.273 | 0.864 | 0.136 | |
| Lean | Obesity | 0.121 | 0.132 | 0.000 | 1.000 | 0.000 | |||
| Cancer | 4 | Healthy | Cancer | 0.011 | 0.007 | 0.000 | 0.000 | 1.000 | |
| HIV | 5 | Negative | Treatment | 0.091 | 0.082 | 0.004 | 0.002 | 0.998 | |
| Negative | Non-treat | 0.091 | 0.064 | 0.000 | 0.000 | 1.000 | |||
| 6 | Negative | Treatment | 0.135 | 0.107 | 0.000 | 0.000 | 1.000 | ||
| Negative | Non-treat | 0.135 | 0.173 | 0.001 | 0.999 | 0.001 | |||
| 7 | Negative | Treatment | 0.136 | 0.158 | 0.012 | 0.994 | 0.006 | ||
| Negative | Non-treat | 0.136 | 0.095 | 0.002 | 0.001 | 0.999 | |||
| T1D (Lean) | 8 | H | T1D | 0.119 | 0.131 | 0.274 | 0.863 | 0.137 | |
| HO | T1DO | 0.156 | 0.143 | 0.881 | 0.560 | 0.440 | |||
| Gout | 9 | Healthy | Gout | 0.164 | 0.102 | 0.000 | 0.000 | 1.000 | |
| MHE | 10 | Healthy | MHE | 0.062 | 0.072 | 0.043 | 0.979 | 0.021 | |
| Control | MHE | 0.058 | 0.072 | 0.000 | 1.000 | 0.000 | |||
| Parkinson's Disease | 11 | Healthy | PD | 0.131 | 0.104 | 0.000 | 0.000 | 1.000 | |
| Schizophrenia | 12 | Healthy | Diseased | 0.141 | 0.117 | 0.000 | 0.000 | 1.000 | |
| Autism | 13 | Healthy | Autism | 0.092 | 0.160 | 0.000 | 1.000 | 0.000 | |
| Healthy | Neurotypical | 0.092 | 0.132 | 0.000 | 1.000 | 0.000 | |||
| Atherosclerosis | 14 | Healthy | Diseased | 0.080 | 0.071 | 0.062 | 0.031 | 0.969 | |
| Intra-H (healthy) treatments | Mean | 0.138 | NA | ||||||
| Std. Err. | 0.015 | ||||||||
| Intra-D (diseased) treatments | Mean | 0.118 | |||||||
| Std. Err. | 0.010 | ||||||||
| % With significant differences between intra-H and intra-D treatments | NA | 72.5 (29/40) | 50.0 (20/40) | 30.0 (12/40) | |||||
| % Without significant differences between intra-H and intra-D treatments | 27.5 (11/40) | 50.0 (20/40) | 70.0 (28/40) | ||||||
| AKP (%) | 50% (20/40) | ||||||||
| Anti-AKP (%) | 30% (12/40) | ||||||||
| Non-AKP (%) | 27.5% (11/40) | ||||||||
CD, Crohn's Disease; UC, Ulcerative Colitis; T1D, Type-1 Diabetes; T1DO, Type-1 Diabetes)(Obese); MHE, Minimal Hepatic Encephalopathy; PD, Parkinson’s Disease.
Summarized from Table S4.